Stay updated on FB825 Safety & Efficacy in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the FB825 Safety & Efficacy in Atopic Dermatitis Clinical Trial page.

Latest updates to the FB825 Safety & Efficacy in Atopic Dermatitis Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe study page now displays an error page instead of the study details. This indicates the record is unavailable and the rich trial information cannot be accessed.SummaryDifference17%

- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedThe page shows a revision tag updated from v3.6.3 to v3.6.4, indicating a new version of the study record on ClinicalTrials.gov.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page now displays a new software revision label, updating from v3.6.2 to v3.6.3. This indicates a minor update to the site's underlying version rather than a change to the study data or user-facing content.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a recent minor update to the page's documentation or metadata. This does not alter substantive study details or user-facing content.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page now indicates that enrollment has ended and adds new guidance sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') along with a header update ('Intervention/Treatment') and a revision note (Revision: v3.6.0), reflecting navigation and informational updates.SummaryDifference0.5%

- Check79 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5. This indicates a small version bump and does not modify substantive content.SummaryDifference0.1%

Stay in the know with updates to FB825 Safety & Efficacy in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FB825 Safety & Efficacy in Atopic Dermatitis Clinical Trial page.